Enliven Therapeutics makes up 2.7% of Stempoint Capital LP’s investment portfolio, making the stock its 10th biggest holding. Stempoint Capital LP owned 0.60% of Enliven Therapeutics as of its most recent SEC filing. Get Enliven Therapeutics alerts:Enliven Therapeutics Trading Down 1.5%NASDAQ:ELVN opened at $52.97 on Thursday. Enliven Therapeutics Company Profile(Free Report)Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Further ReadingReceive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.